Back

Differential effects of androgen deprivation therapy modalities on platelet phenotype: results from an exploratory clinical study

19 June 2026 (15:55 - 16:10)
Organised by: Logo
Congress Presentation Part of: Androgen deprivation therapy in prostate cancer and cardiovascular risk: mechanistic and clinical considerations Cardiovascular Toxicity of Cancer Therapies Open Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Antonia Beitzen Heineke

Hamburg (Germany)

3 More presentations in this session

Presentation thumbnail
Introduction: epidemiological data and current evidence of androgen deprivation therapy associated cardiovascular effects
Professor S. Szmit (Warsaw, PL)
Presentation thumbnail
Cardiovascular effects associated with androgen deprivation therapy: current mechanistic understanding, clinical relevance, and limitations
Doctor B. Terol (Madrid, ES)
Presentation thumbnail
Conclusion

Access the full session

Session thumbnail
Androgen deprivation therapy in prostate cancer and cardiovascular risk: mechanistic and clinical considerations

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 15:55 CET
You may be interested in
thumbnail
Congress Presentation
Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy
30 August 2025
thumbnail
Congress Presentation
Androgen deprivation therapy with agonists of GnRH: cardiovascular adverse events and comorbidity considerations in patients with prostate cancer
27 August 2021
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?
14 March 2025
thumbnail
Congress Presentation
Thrombin generation and platelet function in patients on RAAS inhibitors
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources